Angelo Maria Patti
Overview
Explore the profile of Angelo Maria Patti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rizza V, Tondi L, Patti A, Cecchi D, Lombardi M, Perone F, et al.
Int J Cardiol Cardiovasc Risk Prev
. 2024 Dec;
23:200338.
PMID: 39734497
Diabetes mellitus (DM) is one of the most prevalent cardiovascular risk factors in the general population, being associated with high morbidity and socioeconomic burden. Diabetic cardiomyopathy (DCM) is a non-negligible...
2.
Salmen T, Potcovaru C, Bica I, Giglio R, Patti A, Stoica R, et al.
Pharmaceuticals (Basel)
. 2024 Oct;
17(10).
PMID: 39458963
This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven...
3.
Gluvic Z, Obradovic M, Manojlovic M, Giglio R, Patti A, Ciaccio M, et al.
Mol Cell Endocrinol
. 2024 Jul;
592:112325.
PMID: 38968968
Polymetabolic syndrome achieved pandemic proportions and dramatically influenced public health systems functioning worldwide. Chronic vascular complications are the major contributors to increased morbidity, disability, and mortality rates in diabetes patients....
4.
Al Hashmi K, Giglio R, Pantea Stoian A, Patti A, Al Waili K, Al Rasadi K, et al.
Front Nutr
. 2024 Apr;
11:1355732.
PMID: 38567250
The definition of "Metabolic Associated Fatty Liver Disease - MAFLD" has replaced the previous definition of Nonalcoholic Fatty Liver Disease (NAFLD), because cardiometabolic criteria have been added for the prevention...
5.
Giglio R, Muzurovic E, Patti A, Toth P, Agarwal M, Almahmeed W, et al.
J Cardiovasc Pharmacol Ther
. 2023 Jul;
28:10742484231186855.
PMID: 37448204
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are low-density lipoprotein cholesterol (LDL-C)-lowering drugs that play a critical role in lipoprotein clearance and metabolism. PCSK9i are used in patients with familial...
6.
Patti A, Giglio R, Allotta A, Bruno A, Di Bella T, Pantea Stoian A, et al.
Biomedicines
. 2023 May;
11(5).
PMID: 37239033
Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in...
7.
Giglio R, Patti A, Rizvi A, Stoian A, Ciaccio M, Papanas N, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36830828
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. Its pathogenesis encompasses functional alterations involving elevated intraglomerular and systemic pressure, increased activity of the renin-angiotensin system...
8.
Cuttitta G, Ferraro M, Cibella F, Alfano P, Bucchieri S, Patti A, et al.
Biomolecules
. 2023 Jan;
13(1).
PMID: 36671433
Adipose tissue is an endocrine organ that interferes with the severity of chronic obstructive pulmonary disease (COPD). Although inflammatory markers, body composition, and nutritional status have a significant impact on...
9.
Giglio R, Papanas N, Rizvi A, Ciaccio M, Patti A, Ilias I, et al.
Medicina (Kaunas)
. 2022 Oct;
58(10).
PMID: 36295635
Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists ("glitazones")...
10.
Patti A, Giglio R, Papanas N, Serban D, Pantea Stoian A, Pafili K, et al.
Medicina (Kaunas)
. 2022 Jan;
58(1).
PMID: 35056417
The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids,...